• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Italy Pharmaceuticals and Healthcare Report Q2 2012 - Product Image

Italy Pharmaceuticals and Healthcare Report Q2 2012

  • Published: February 2012
  • Region: Italy
  • 82 Pages
  • Business Monitor International


  • GlaxoSmithKline
  • Menarini
  • Merck & Co
  • Multinational Companies
  • Novartis
  • Pfizer
  • MORE

Business Monitor International's Italy Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Italy's pharmaceuticals and healthcare industry.

BMI View: The pharmaceuticals and healthcare sector will be a target of further cost containment, particularly as National Health System (SSN) data for H111, which shows a decline in spending, highlights the success of previous cost-containment efforts.

Headline Expenditure Projections
- Pharmaceuticals: EUR24.90bn (US$34.63bn) in 2011 to EUR23.52bn (US$31.52bn) in 2012; -5.5% in local currency terms (-9.0% in US dollar terms).
- Healthcare: EUR151.85bn (US$211.19bn) in 2011 to EUR154.02bn (US$206.39bn) in 2012; +1.4% growth in local currency terms (-2.3% in US dollar terms).
- Medical devices: EUR6.42bn (US$8.93bn) in 2011 to EUR6.61bn (US$8.86n) in 2012; +2.9% growth in local currency terms (-0.8% in US dollar terms).

Risk/Reward Rating: In BMIs Pharmaceuticals and Healthcare Risk/Reward (RRRs) for Q212, Italy is eighth out of READ MORE >

Executive Summary

SWOT Analysis
Italy Pharmaceuticals And Healthcare Industry SWOT
Italy Political SWOT
Italy Economic SWOT
Italy Business Environment SWOT

Pharmaceuticals Risk/Reward Ratings
Table: Western Europe Pharmaceuticals And Healthcare Risk/Reward Ratings, Q212
Italy – Market Summary
Regulatory Regime
Table: Pharmaceutical Status Switches

Intellectual Property Developments
Pricing Regime
Reimbursement Regime

Industry Developments
Healthcare Sector
Clinical Trials
Medical Devices

Industry Forecast Scenario
Overall Market Forecast
Table: Pharmaceutical Sales, 2008-2016

Key Growth Drivers – Industry
Table: Overall Healthcare Expenditure, 2008-2016
Table: Governmental Healthcare Expenditure, 2008-2016
Table: Private Healthcare Expenditure, 2008-2016

Key Growth Drivers – Macroeconomic
Table: GDP By Expenditure, Current Prices Breakdown, 2008-2016
Prescription Drug Market Forecast
Table: Prescription Drug Sales, 2008-2016
Patented Drug Market Forecast
Table: Patented Drug Sales, 2008-2016
Generic Drug Market Forecast
Table: Generic Drug Sales, 2008-2016
OTC Medicine Market Forecast
Table: OTC Medicine Sales, 2008-2016
Medical Device Market Forecast
Table: Medical Devices Sales, 2008-2016
Pharmaceutical Trade Forecast
Table: Pharmaceutical Trade, 2008-2016

Other Healthcare Data Forecasts

Key Risk To BMI’s Forecasts

Competitive Landscape
Pharmaceutical Industry
Table: Leading Local Healthcare Companies By Market Capitalisation
Recent Company Developments
Pharmaceutical Wholesale Sector
Retail Pharmacy Sector

Company Profiles
Local Companies
Multinational Companies
Merck & Co

Country Snapshot: Italy Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2002-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 2001-2006
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Manufacturing Wages, 2000-2012

BMI Methodology
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Risk/Reward Ratings Methodology
Ratings Overview
Table: Pharmaceutical Risk/Reward Indicators
Table: Weighting Of Components

- Recordati
- Menarini
- Multinational Companies
- GlaxoSmithKline
- Pfizer
- Novartis
- Sanofi
- Merck & Co

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos